Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-6306 in Patients With Advanced Cancer
NCT05605509Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lunresertib in cancer, endometrial cancer (EC), ovarian cancer and 6 more (4 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate at 2 years. Started May 2023; status: completed.
02
Drugs
lunresertib
03
Conditions
cancerendometrial cancer (EC)ovarian canceruterine carcinosarcoma (UCS)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05605509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605509.